INmune Bio stock soars after prostate cancer trial meets endpoints

Published 04/08/2025, 13:22
© Reuters.

Investing.com -- INmune Bio Inc. (NASDAQ:INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both primary and secondary endpoints and is now closed to enrollment.

The clinical-stage immunology and inflammation company reported that INKmune™ demonstrated an excellent safety profile at all three dose levels tested in the "CaRe PC" trial, achieving the primary endpoint. Additionally, patients with low natural killer (NK) cell activation showed the greatest improvement in biomarkers of NK cell activation, helping define the target population for future trials.

"INKmune was safe and effective at activating NK cells in a subset of more than half of these patients with advanced disease," said Dr. Mark Lowdell, CSO at INmune Bio. "Excitingly we did see, in some patients, individual tumor lesions either reducing in size or completely disappearing during treatment, so we believe this could be evidence of a direct effect on tumor cell killing."

Following these positive results, INmune Bio plans to advance the program by designing a randomized Phase 2b trial in patients with less severe disease. This approach aims to enable more robust measurement of the drug’s effects and potential clinical benefits.

The company’s shares responded strongly to the announcement as investors appeared to welcome the positive trial results and advancement of the INKmune™ program.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.